Abstract
Drug-drug interactions (DDIs) are of great concern in the treatment of cancer, especially when target therapies, such as tyrosine kinase inhibitors, are being used. Here, we report a case of probable DDI between erlotinib and amiodarone leading to severe neurotoxicity. Amiodarone inhibits P-glycoprotein (P-gp), for which erlotinib is a substrate. P-gp is an important drug transporter that is involved in limiting the blood-brain barrier penetration of erlotinib. Clinicians should be aware of emerging data characterizing the effect of the P-gp transport system on drug exposure and its potential for DDI.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
-
Amiodarone / adverse effects*
-
Amiodarone / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / radiotherapy
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / radiotherapy
-
Disease Progression
-
Drug Interactions
-
Erlotinib Hydrochloride / adverse effects*
-
Erlotinib Hydrochloride / therapeutic use
-
Humans
-
Induction Chemotherapy
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Paralysis / etiology
-
Radiotherapy
-
Withholding Treatment
Substances
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Erlotinib Hydrochloride
-
Amiodarone